This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bissett, D. Articles by Shepherd, F. A. Search for Related Content PubMed PubMed Citation Articles by Bissett, D. Articles by Shepherd, F. A. Social Bookmarking                            What's this?

Phase III Study of Matrix Metalloproteinase Inhibitor Prinomastat in Non–Small-Cell Lung Cancer

From the Aberdeen Royal Infirmary, Aberdeen; Leicester Royal Infirmary, Leicester; University of Edinburgh, Edinburgh, United Kingdom; Asklepios Fachkliniken, München-Gauting; Krankenhaus Grosshansdorf, Grosshansdorf, Germany; Marshfield Clinic, Marshfield, WI; Pfizer Global Research and Development, La Jolla, CA; and Princess Margaret Hospital, Toronto, Ontario, Canada

Address reprint requests to Donald Bissett, MD, Department of Clinical Oncology, Clinic D, Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, United Kingdom; e-mail: d.bissett{at}arh.grampian.scot.nhs.uk

PURPOSE: Matrix metalloproteinases (MMPs) degrade extracellular proteins and facilitate tumor growth, invasion, metastasis, and angiogenesis. This trial was undertaken to determine the effect of prinomastat, an inhibitor of selected MMPs, on the survival of patients with advanced non–small-cell lung cancer (NSCLC), when given in combination with gemcitabine-cisplatin chemotherapy.

PATIENTS AND METHODS: Chemotherapy-naive patients were randomly assigned to receive prinomastat 15 mg or placebo twice daily orally continuously, in combination with gemcitabine 1,250 mg/m² days 1 and 8 plus cisplatin 75 mg/m² day 1, every 21 days for up to six cycles. The planned sample size was 420 patients.

RESULTS: Study results at an interim analysis and lack of efficacy in another phase III trial prompted early closure of this study. There were 362 patients randomized (181 on prinomastat and 181 on placebo). One hundred thirty-four patients had stage IIIB disease with T4 primary tumor, 193 had stage IV disease, and 34 had recurrent disease (one enrolled patient was ineligible with stage IIIA disease). Overall response rates for the two treatment arms were similar (27% for prinomastat v 26% for placebo; P = .81). There was no difference in overall survival or time to progression; for prinomastat versus placebo patients, the median overall survival times were 11.5 versus 10.8 months (P = .82), 1-year survival rates were 43% v 38% (P = .45), and progression-free survival times were 6.1 v 5.5 months (P = .11), respectively. The toxicities of prinomastat were arthralgia, stiffness, and joint swelling. Treatment interruption was required in 38% of prinomastat patients and 12% of placebo patients.

CONCLUSION: Prinomastat does not improve the outcome of chemotherapy in advanced NSCLC.

Supported by a project grant from Pfizer Pharmaceuticals.

Presented in part at the 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 18-21, 2002.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Manegold, D. Gravenor, D. Woytowitz, J. Mezger, V. Hirsh, G. Albert, M. Al-Adhami, D. Readett, A. M. Krieg, and C. G. Leichman Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non-Small-Cell Lung Cancer J. Clin. Oncol., August 20, 2008; 26(24): 3979 - 3986. [Abstract] [Full Text] [PDF]

				G. S. Butler, R. A. Dean, E. M. Tam, and C. M. Overall Pharmacoproteomics of a Metalloproteinase Hydroxamate Inhibitor in Breast Cancer Cells: Dynamics of Membrane Type 1 Matrix Metalloproteinase-Mediated Membrane Protein Shedding Mol. Cell. Biol., August 1, 2008; 28(15): 4896 - 4914. [Abstract] [Full Text] [PDF]

				C. K. Daugherty, M. J. Ratain, E. J. Emanuel, A. T. Farrell, and R. L. Schilsky Ethical, Scientific, and Regulatory Perspectives Regarding the Use of Placebos in Cancer Clinical Trials J. Clin. Oncol., March 10, 2008; 26(8): 1371 - 1378. [Abstract] [Full Text] [PDF]

				M. A. Socinski, R. Crowell, T. E. Hensing, C. J. Langer, R. Lilenbaum, A. B. Sandler, and D. Morris Treatment of Non-small Cell Lung Cancer, Stage IV: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 277S - 289S. [Abstract] [Full Text] [PDF]

				R. L. Schilsky Target practice: oncology drug development in the era of genomic medicine Clinical Trials, April 1, 2007; 4(2): 163 - 166. [PDF]

				W. M. Stadler The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents Mol. Cancer Ther., April 1, 2007; 6(4): 1180 - 1185. [Abstract] [Full Text] [PDF]

				A. A. Chiappori, S. G. Eckhardt, R. Bukowski, D. M. Sullivan, M. Ikeda, Y. Yano, T. Yamada-Sawada, Y. Kambayashi, K. Tanaka, M. M. Javle, et al. A Phase I Pharmacokinetic and Pharmacodynamic Study of S-3304, a Novel Matrix Metalloproteinase Inhibitor, in Patients with Advanced and Refractory Solid Tumors Clin. Cancer Res., April 1, 2007; 13(7): 2091 - 2099. [Abstract] [Full Text] [PDF]

				A. Y. Savinov, D. V. Rozanov, and A. Y. Strongin Mechanistic insights into targeting T cell membrane proteinase to promote islet {beta}-cell rejuvenation in type 1 diabetes FASEB J, September 1, 2006; 20(11): 1793 - 1801. [Abstract] [Full Text] [PDF]

				D. H. Johnson Targeted therapies in combination with chemotherapy in non-small cell lung cancer. Clin. Cancer Res., July 15, 2006; 12(14): 4451s - 4457s. [Abstract] [Full Text] [PDF]